Free Trial

Sagimet Biosciences (SGMT) Competitors

Sagimet Biosciences logo
$3.41 +0.19 (+5.90%)
Closing price 04:00 PM Eastern
Extended Trading
$3.41 0.00 (0.00%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SGMT vs. ABVX, TRML, PGEN, RGNX, MREO, ERAS, KMDA, VERV, TECX, and ORIC

Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include ABIVAX Société Anonyme (ABVX), Tourmaline Bio (TRML), Precigen (PGEN), REGENXBIO (RGNX), Mereo BioPharma Group (MREO), Erasca (ERAS), Kamada (KMDA), Verve Therapeutics (VERV), Tectonic Therapeutic (TECX), and ORIC Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry.

Sagimet Biosciences vs.

Sagimet Biosciences (NASDAQ:SGMT) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability.

Sagimet Biosciences has higher revenue and earnings than ABIVAX Société Anonyme.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sagimet Biosciences$2M52.30-$27.88M-$1.76-1.94
ABIVAX Société AnonymeN/AN/A-$159.90MN/AN/A

ABIVAX Société Anonyme's return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Sagimet BiosciencesN/A -23.63% -22.91%
ABIVAX Société Anonyme N/A N/A N/A

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sagimet Biosciences received 17 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. Likewise, 96.43% of users gave Sagimet Biosciences an outperform vote while only 76.92% of users gave ABIVAX Société Anonyme an outperform vote.

CompanyUnderperformOutperform
Sagimet BiosciencesOutperform Votes
27
96.43%
Underperform Votes
1
3.57%
ABIVAX Société AnonymeOutperform Votes
10
76.92%
Underperform Votes
3
23.08%

In the previous week, Sagimet Biosciences had 1 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 3 mentions for Sagimet Biosciences and 2 mentions for ABIVAX Société Anonyme. ABIVAX Société Anonyme's average media sentiment score of 0.87 beat Sagimet Biosciences' score of 0.00 indicating that ABIVAX Société Anonyme is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sagimet Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
ABIVAX Société Anonyme
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Sagimet Biosciences has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, ABIVAX Société Anonyme has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Sagimet Biosciences presently has a consensus target price of $22.40, indicating a potential upside of 556.89%. ABIVAX Société Anonyme has a consensus target price of $31.00, indicating a potential upside of 412.40%. Given Sagimet Biosciences' higher probable upside, equities analysts plainly believe Sagimet Biosciences is more favorable than ABIVAX Société Anonyme.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sagimet Biosciences
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
ABIVAX Société Anonyme
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Sagimet Biosciences beats ABIVAX Société Anonyme on 10 of the 15 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SGMT vs. The Competition

MetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$104.60M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-1.949.0626.7119.71
Price / Sales52.30251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book0.866.456.774.50
Net Income-$27.88M$143.98M$3.23B$248.22M
7 Day Performance3.02%2.41%1.80%0.56%
1 Month Performance33.73%4.56%11.10%13.17%
1 Year Performance-32.87%-2.67%17.11%7.30%

Sagimet Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SGMT
Sagimet Biosciences
1.5847 of 5 stars
$3.41
+5.9%
$22.40
+556.9%
-32.8%$104.60M$2M-1.948
ABVX
ABIVAX Société Anonyme
2.4466 of 5 stars
$6.40
-4.6%
$34.00
+431.3%
-59.3%$405.88MN/A0.0061
TRML
Tourmaline Bio
1.8613 of 5 stars
$15.78
+4.5%
$49.33
+212.6%
+7.7%$405.31MN/A-5.6044
PGEN
Precigen
3.3849 of 5 stars
$1.37
+3.0%
$7.00
+410.9%
-5.0%$404.38M$3.93M-2.49190News Coverage
Analyst Revision
High Trading Volume
RGNX
REGENXBIO
4.1975 of 5 stars
$7.97
+6.0%
$31.63
+296.8%
-37.1%$399.43M$83.33M-1.58370Analyst Revision
MREO
Mereo BioPharma Group
1.9263 of 5 stars
$2.50
+3.7%
$7.71
+208.6%
-26.3%$397.50M$1M-41.6740Positive News
Gap Up
ERAS
Erasca
3.5938 of 5 stars
$1.39
flat
$4.83
+247.7%
-48.1%$393.77MN/A-1.67120Positive News
KMDA
Kamada
3.9227 of 5 stars
$6.82
-0.9%
$14.67
+115.1%
+28.9%$392.01M$160.95M24.36360Analyst Upgrade
Analyst Revision
VERV
Verve Therapeutics
3.513 of 5 stars
$4.35
+2.8%
$25.75
+492.0%
-23.6%$387.77M$32.33M-1.77110Trending News
Analyst Upgrade
Analyst Revision
TECX
Tectonic Therapeutic
3.596 of 5 stars
$20.71
+4.8%
$72.40
+249.6%
N/A$386.68MN/A-3.52120
ORIC
ORIC Pharmaceuticals
4.4264 of 5 stars
$5.41
+6.5%
$19.17
+254.3%
-34.0%$384.59MN/A-2.9780Positive News

Related Companies and Tools


This page (NASDAQ:SGMT) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners